Chief executive Pascal Soriot said AstraZeneca faced a “transitional period” due to the expiry of Crestor’s US patent in May, but the company was poised for a comeback and it would continue to plough investment into drug research

AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling c(...)

Ryanair CEO Michael O’Leary: results due Monday. Photograph:  EPA/OLIVIER HOSLET
For your diary

TODAY Results: Alphabet; Bankia; LG; Ryanair; Universal. Indicators: Irish Investec manufacturing PMI (Jan); German Markit manufacturing PMI (Jan); eu(...)

Traders work on the floor of the New York Stock Exchange. US stocks advanced to a three-week high in early trading, helping trim the first annual loss for global equities since 2011.

European stock markets rose, helped by gains in the banking sector, although weaker mining share prices held back the London market and trading activi(...)

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine.

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine. The UK’s second-large(...)

AstraZeneca acquired the US rights for the drug roflumilast  from Actavis earlier this year as part of a deal that bolstered its respiratory business, one of the company’s three main areas of focus. Photograph: Simon Dawson/Bloomberg

Britain’s AstraZeneca has agreed to buy Takeda Pharmaceutical’s respiratory business, including expanded rights to roflumilast, a treatment for chroni(...)

AstraZeneca has confirmed it is in  talks with privately held cancer drug developer Acerta Pharma.

AstraZeneca has confirmed it is in talks with privately held cancer drug developer Acerta Pharma. The Wall Street Journal reported on Friday that As(...)

Pfizer and Allergan would have to pay the other party just $400 million if either were to pull out of their $160 billion deal due to a change in th(...)

Jack Lew: The latest efforts by the US treasury secretary   to clamp down on inversions are irrelevant for the Pfizer deal, which meets previous thresholds laid down by his department for inversions.   Photograph: Simon Dawson/Bloomberg

The spluttering from Washington can be heard clearly across the Atlantic. The trouble is that the more it squares up on inversions, the more the Unite(...)

Pfizer’s plant at Newbridge, Co Kildare Photograph: Reuters

Pfizer is in advanced talks to buy Irish-based Allergan for as much as $380 (€353) per share, valuing the Botox maker at as much as $150 billion - if (...)

Pfizer is in negotiations with Dublin-based Allergan about buying the group in what would be the biggest ever “tax inversion” — allowing the company to report much lower tax costs by moving its domicile to Ireland. (Photograph: Scott Eisen/Bloomberg)

The chief executive of Allergan, in talks about selling itself to Pfizer to form the world’s largest drugmaker, has cautioned that any attempt by the(...)